US Patent Issued to Amniotics on Oct. 7 for "Immunomodulation by amniotic fluid mesenchymal stem cells" (Swedish, Danish Inventors)

ALEXANDRIA, Va., Oct. 8 -- United States Patent no. 12,435,308, issued on Oct. 7, was assigned to Amniotics AB (Lund, Sweden).

"Immunomodulation by amniotic fluid mesenchymal stem cells" was invented by Jan Talts (Staffanstorp, Sweden) and Kare Engkilde (Vaerlose, Denmark).

According to the abstract* released by the U.S. Patent & Trademark Office: "Methods of reducing T cell activation including co-culturing with T cells, term amniotic fluid mesenchymal stem cells (TAF-MSCs) isolated from term human amniotic fluid. Other aspects relate to methods of inhibiting macrophage polarization toward the M1 pro-inflammatory phenotype including co-culturing with macrophages TAF-MSCs isolated from term human amniotic fluid. Other aspects relate to me...